Screener
BioCryst Pharmaceuticals BCRX Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShortTermInvestments.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $154,972 | $89,736 |
| Restricted cash | 479 | 201 |
| Short-term investments | 197,601 | 185,011 |
| Trade receivables | 110,757 | 106,818 |
| Inventory, net | 6,056 | 5,398 |
| Prepaid expenses and other current assets | 14,818 | 17,182 |
| Total current assets | 484,683 | 404,346 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's short-term investments?
- BioCryst Pharmaceuticals (BCRX) reported short-term investments of $197.6M in Q2 2026.
- How has BioCryst Pharmaceuticals's short-term investments changed year-over-year?
- BioCryst Pharmaceuticals's short-term investments increased by 14.9% year-over-year, from $172.01M to $197.6M.
- What is the long-term trend for BioCryst Pharmaceuticals's short-term investments?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's short-term investments has grown at a 45.6% compound annual growth rate (CAGR), from $28.24M to $185.01M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about BioCryst Pharmaceuticals's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude